No silly question when it comes to biotech.
To answer your question the Phase I trial will be an "all comers” trial where patients with any cancer type can be included. This should make the trial recruit relatively fast (you are not looking for a specific cancer type) as well as offer the opportunity to even show efficacy given how frequently FTO is overexpressed in cancer.
I don’t think it would be ethical to give healthy people Bisantrene at this stage even at low doses.
Ann: Race investor briefing & updated presentation, page-35
-
- There are more pages in this discussion • 300 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.94 |
Change
0.000(0.00%) |
Mkt cap ! $330.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1358 | $1.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.94 | 5654 | 2 |
View Market Depth
| Last trade - 07.01am 16/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |
Day chart unavailable